Cumberland Pharmaceuticals (NASDAQ:CPIX) Releases Earnings Results

Key Points

• Cumberland Pharmaceuticals reported earnings of $0.02 per share for the quarter, with a negative net margin of 7.98% and a positive return on equity of 6.92%.
• The company's stock has declined by 5.5%, currently trading at $3.79, compared to its 50-day moving average of $4.15.
• Analysts upgraded Cumberland Pharmaceuticals from a "buy" rating to a "strong-buy" rating, indicating increased investor confidence.

Cumberland Pharmaceuticals (NASDAQ:CPIX - Get Free Report) announced its earnings results on Tuesday. The specialty pharmaceutical company reported $0.02 earnings per share for the quarter, Zacks reports. Cumberland Pharmaceuticals had a negative net margin of 6.97% and a positive return on equity of 7.68%.

Cumberland Pharmaceuticals Price Performance

CPIX stock traded up $0.07 during trading on Thursday, hitting $3.28. The stock had a trading volume of 78,172 shares, compared to its average volume of 702,458. Cumberland Pharmaceuticals has a 1-year low of $1.04 and a 1-year high of $7.25. The company's 50 day moving average price is $4.06 and its two-hundred day moving average price is $4.41. The company has a debt-to-equity ratio of 0.18, a quick ratio of 1.09 and a current ratio of 1.25. The stock has a market cap of $49.07 million, a price-to-earnings ratio of -14.91 and a beta of -0.39.

Analysts Set New Price Targets

Separately, Wall Street Zen raised shares of Cumberland Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research note on Thursday, May 8th.

About Cumberland Pharmaceuticals

Cumberland Pharmaceuticals Inc, a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, and oncology in the United States and internationally. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of constipation; Omeclamox-Pak for the treatment of Helicobacter pylori infection and duodenal ulcer disease; Vaprisol, an injection for treating euvolemic and hypervolemic hyponatremia; Sancuso, an injection for the treatment of chemotherapy treatment; and Vibativ, an injection for the treatment of certain serious bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections.